“A combination attack on androgens in metastatic prostate cancer resistant to initial hormone therapy drove down testosterone levels and appeared safe, according to a proof of concept study.
“Enzalutamide (Xtandi) plus abiraterone (Zytiga) dropped blood and bone marrow androgens down to undetectable levels for 80% of such patients, reported Eleni Efstathiou, MD, PhD, of the MD Anderson Cancer Center in Houston.
Editor’s note: This article discusses a treatment that may benefit men with metastatic prostate cancer that has become resistant to hormonal therapy (a condition known as castration-resistant prostate cancer or CRPC). The treatment, which combines the drugs enzalutamide (Xtandi) and abiraterone (Zytiga), was tested in a study with volunteer patients. The treatment appeared safe and also lowered testosterone levels—a promising sign that indicates potential cancer-fighting power. More studies will have to be done to determine just how well the treatment might work.